Eklira Sucks Customer Reviews and Feedback
Aclidinium bromide is a long-acting, inhaled muscarinic antagonist approved in the United States on July 24, 2012, as a maintenance treatment for chronic obstructive pulmonary disease. Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD. However, it does not appear to affect the risk of death or the frequency steroids are needed. It is marketed under the brand name Tudorza Pressair in the US, Eklira Genuair in the UK, and Tudorza Genuair in Canada
Eklira could cause tedious side effects such as inflammation of the nose and throat, sinusitis, cough, nausea, and diarrhea, according to a report published at drugs.com
"The most common side effects with Eklira are headache and nasopharyngitis (inflammation of the nose and throat). Other common side effects are sinusitis (inflammation of the sinuses), cough, nausea (feeling sick), and diarrhea."
In The News
PR Newswire reports"Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight"
PR Newswire reports"Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook"
DirectorsTalk Interviews reports"Astrazeneca PLC - Consensus Indicates Potential 9.4% Upside"
PRNewswire reports"Visiongain publishes Asthma & COPD Therapies Market 2020-2030 report"